Epirox

Ceftriaxone 1G (Ceftriaxone Sodium) for Intravenous and Intramuscular Use. Ceftriaxone 1G is a broad-spectrum cephalosporin antibiotic, presented as a powder for injectable solution, for both intravenous (IV) and intramuscular (IM) use. This medication is designed for the treatment of severe bacterial infections, offering high efficacy against a wide variety of gram-positive and gram-negative pathogens.

Ceftriaxone 1G is indicated for the treatment of various bacterial infections in adults and children, including respiratory infections, skin and soft tissue infections, urinary tract infections, intra-abdominal infections, uncomplicated gonorrhea caused by susceptible Neisseria gonorrhoeae, and bacterial meningitis.

Ceftriaxone is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. It shows high penetration into body tissues and fluids, including cerebrospinal fluid.

Standard dose for adults and children over 12 years: 1G of Ceftriaxone administered once daily or divided into two doses of 500 mg every 12 hours. For severe or critical infections, the dose may be increased to 2-4 G per day. The duration of treatment varies according to the severity and type of infection, but is generally 5 to 14 days. For IV administration, dissolve in sterile solution and administer slowly over at least 30 minutes. For IM administration, dilute in 1% lidocaine to reduce pain at the injection site.

Broad spectrum of antibacterial activity. Convenient once-daily dosing facilitates treatment compliance. Broad-spectrum antibacterial activity against susceptible organisms.

Evaluate the sensitivity of the causative microorganism before starting treatment. No dosage adjustment is generally necessary in patients with isolated renal or hepatic impairment. Use caution in patients with significant renal and hepatic dysfunction. Monitor the response to treatment and adjust therapy as necessary.

Caution in patients with a history of allergic reactions to beta-lactam antibiotics. Monitor for signs of pseudomembranous colitis and other gastrointestinal adverse reactions. Do not use in hyperbilirubinemic neonates. Ceftriaxone is contraindicated in neonates ≤28 days who require or are expected to require calcium-containing IV solutions.

Epirox contains Ceftriaxone sodium USP 1.0 g and is presented in a box of 10 and 50 vials, following the United States Pharmacopeia standard.

Manufactured according to the strict specifications of the United States Pharmacopeia to ensure consistency and superior quality. Crassula Pharma certifies that all our products are manufactured in accordance with GMP parameters.